AR 13

Drug Profile

AR 13

Alternative Names: AR-13

Latest Information Update: 12 Oct 2015

Price : $50

At a glance

  • Originator Arno Therapeutics
  • Class Small molecules
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 24 Sep 2015 Antimicrobial data from a preclinical study in Cystic fibrosis released by Arno Therapeutics
  • 01 Sep 2015 Preclinical trials in Cystic fibrosis in USA (unspecified route) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top